Downloading...
Download

AMRX

Amneal Announces Over $270M In US Opioid Lawsuit SettlementAmneal Pharmaceuticals ( NASDAQ:AMRX ) has announced a $270 million settlement to settle claims related to its alleged contribution to the opioid crisis in the U.S. The agreement, payable over a decade, aims to address a substantial portion of the more than 900 opioid-related lawsuits facing the company. State attorneys general have accused Amneal ( NASDAQ:AMRX ) of inadequately monitoring and reporting suspicious orders of generic opioid medications by its customers. Allegations suggest that the company distributed nearly nine billion pills from 2006 to 2019, further exacerbating the crisis. Amneal Pharmaceuticals ( NASDAQ:AMRX ) reported first-quarter adjusted EPS of $0.14, up from $0.12 a year ago, beating the consensus of $0.09. The company reported sales of $659.2 million, up 8%, beating the consensus of $619.03 million. Generics revenues increased by 14% due to strong performance in complex generics, oncology biosimilars, and new launches. Specialty revenues increased by 15%, driven by promoted products in neurology and endocrinology. AvKARE revenues increased 33%, driven by continued expansion across its channels due to new products. Amneal ( NASDAQ:AMRX ) reaffirms fiscal year 2024 revenue guidance of $2.55 billion-$2.65 billion versus the consensus of $2.60 billion, with an adjusted EPS of $0.53-$0.63 compared to the consensus of $0.58. AMRX shares are up 9.55% at $6.80 at last check Friday.
NASDAQ:AMRXLong
by DEXWireNews
AADI - NASDAQ PENNY Biotech pre-earnings LONGAADI has earnings in two day. On the 30 minute chart, it is significantly below the highs of May and June where it was in a wide ranged consolidation. After that in July price trended down along the support of the second lower VWAP line into a reversal on August 1 shich also ascended the VWAP lines. Upcoming earnings are in two days on the 9th. Prior two earning reports lightly beat the top and bottom lines. This small biotechnology company is making money unlike many of its cash-burning peers. The zero-lag MAC shows a line cross under the histogram which flipped red to green as the lines rise. With this confirmation, I will take a long trade into the earnings. There is no alternative in a call option in this case. From the chart, targets are 6.9, 6.9, and 8.0 over a stop loss of 5.45. I expect this trade to be finished in 4 days or less.
ALong
by AwesomeAvani
1
AMRX Biotech earnings Today LONGAMRX is a penny biotechnology stock with earnings out on the Friday the 4th. As you can see on the 15 minute chart, it took off out of consolidation on Wednesday afternoon in a burst of price volume and volatility into an ascending parallel channel. I will buy the stock in the pre-market attempting to exploit the momentum going into earnings. If there is a miss, I will quickly liquidate and instead buy put options expiring on 8/18 striking $ 5 and get as many as 100 of them. This will be a highly risky trade albeit with a comparable reward. I will position to 0.05% of my account cash balance and no more.
ALong
by AwesomeAvani
Wyckoff is SimpleThe wyckoff method is a very simple method. The purpose of this post is to show you price manipulation by the Composite Operator or CO. Price NEVER moves the same way. In fact, you will almost never see the same wyckoff pattern in all of your trading years. HOWEVER, the terminology is the same because the reasoning behind these moves are scientific and are inevitably going to happen. For example, shorts have to cover eventually. Thus, the terminology for the automatic rally after a long downtrend is Sufficient evidence of short covering. So, In almost every range there will be a stage. A stopping stage, trading stage, heavy absorption or distribution, trend phases, and an exit of the range. By far, this method of trading is the BEST way to avoid excessive risk, and if you are lucky, you can easily campaign a stock into 200-300% gains--EVEN IN PHASE B?!?!( big risk )
AShort
by Integrity_Investments
AMRX 1D RANGE TRADESRanges are repeatable trading chart patterns. Ranges are consolidation chart patterns that can breakout either direction. Each chart pattern will have defining trendlines of the support/resistance levels creating the pattern. What ever time frame you are trading this chart pattern, wait for a candle close outside of the trendline in the direction of the breakout candle. (Our time frame preference is the Daily chart). Add volume indicator - Volume is the amount of $ that went into a particular candle or in Forex the # of trades that took place. Add ATR indicator - Volatility is the amount of price movement that occurred. Use the ATR to measure the price movement. When you see descending Volume bars and descending ATR line (which indicates volatility) this shows a dis-interest in traders to invest in this pair creating consolidation which creates the chart pattern. Trade Management after there is a breakout candle close. 1 - Position size (compare volume bar to volume ma line). a - Breakout candle must be 100% of average volume for a full position size. b - If 75% of average volume then ½ position size. (To find 75% of Volume look at the charts volume settings – divide smaller # into larger # = 75%+) 2 - Enter two trades. 3 - SL for both trades will be 1.5 x ATR. 4 - 1st trade TP will be 1 x ATR. 5 - No TP on 2nd trade – letting profit run and adjusting SL to follow price. 6 - When 1st TP hit – move 2nd trade SL to breakeven. 7 - Adjust the 2nd trade SL to follow price. *8 – After Breakout candle – if price closes back into chart pattern close trade *9 - When breakout candle is more than 1 ATR from breakout candle open. a - Enter 1st trade at candle close with ½ position size. b - Enter 2nd trade with a pending limit order that is 1 ATR of breakout candle open. c – Price should pullback to that pending limit order for 2nd trade. d – If Price returns back into chart pattern close trade before SL is hit.
A
by Tradingstrategyguides
AMRX 4D: BUY/HOLD 200% gains // accumulation (STOCKS)Why get subbed to to me on Tradingview? -TOP author on TradingView -15+ years experience in markets -Professional chart break downs -Supply/Demand Zones -TD9 counts / combo review -Key S/R levels -No junk on my charts -Frequent updates -Covering FX/crypto/US stocks -24/7 uptime so constant updates AMRX 4D: BUY/HOLD 200% gains // accumulation (STOCKS) IMPORTANT NOTE: speculative setup. do your own due dill. use STOP LOSS. don't overleverage. 🔸 Summary and potential trade setup ::: AMRX 4days/candle chart overview ::: strong bullish bottom base ::: accumulation in progress right now ::: final hurdle in the way at 6.50/6.60 USD ::: expecting pullback after resistance ::: STRATEGY: BUY/HOLD pullback 3.60/3.70 ::: BUY/HOLD swing trade setup / patient traders ::: 200%+ gains on BUY SIDE later ::: good luck traders 🔸 Supply/Demand Zones ::: N/A ::: N/A 🔸 Other noteworthy technicals/fundies ::: TD9/Combo update: N/A ::: Sentiment: BULLS ::: Sentiment outlook short-term: BULLS
ALong
by ProjectSyndicate
2
AMRX - WEEK CHART Hi, today we are going to talk about Amneal Pharmaceuticals and its current landscape. The opioid crisis has been plaguing the U.S at the most for nearly two years now. With scary numbers like the record of 47,600* overdose deaths caused by opioids in 2017 but the number seems to start slowdown since 2018 were the war against opioids gained some traction. In the justice field, some companies have already faced some sort of rebuke for involvement and even a bit of responsibility for the opioid crisis. For example *Jun 2019, Insys Therapeutics Inc. had to file for bankruptcy after being convicted for conspiring to bribe doctors to increase opioid sales, ending up in a deal with the federal government of $225 million. * Aug 2019, Johnson & Johnson was obligated to pay $572 Million, as Oklahoma ruled that the company intentionally played down the dangers and oversold the benefits of opioids. * Oct 2019, Johnson & Johnson was once more condemned by two counties of Ohio to pay $20.4 million, with the accusation of having helped the opioid crisis to spread. Now, the drug maker Amneal Pharmaceuticals, is under investigation by the Federal Prosecutors in Brooklyn, into whether the company intentionally permitted that flood of opioids on the community. For now the U.S. Attorney’s Office in the Eastern District of New York it's just issuing subpoenas, but if they case sticks we might see what the murders of Julius Caesar saw, a pile of fire and anger from the people, so big that like Caesar butchers that were cast out of the city, the companies involved on this process can be drowned in liabilities and fines with the risk to be so badly damaged that may have the same fate of Insys Therapeutics Inc. The war against opioids it's just poised to grow up as every justice department across the country and every candidate that it's next to run on elections its eager to hang this trophy on the wall. *Source: Centers for Disease Control and Prevention (CDC) Thank you for reading and leave your comments if you like. To have access to our exclusive contents, join the Traders Heaven today! Link Below. Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.
A
by Igor-Silva